chronic myeloid leukaemia

chronic myeloid leukaemia

An indolent leukaemia, characterised by increased mature granulocytes in the peripheral circulation.

Clinical findings
Often asymptomatic; otherwise with splenomegaly, left sided pain, general malaise, joint pain, low-grade fever, pancytopaenia resulting in increased infections, anaemia, thrombocytopaenia.
 
Genetics
Philadelphia chromosome, a fusion gene bcl-abl from a 9:22 translocation, resulting in a gene product with tyrosine kinase activity.

Management
Imatinib mesylate induces major cytogenetic responses in 60% of patients with chronic-phase CML and complete haematologic responses in 95% of CML patients.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

chronic myeloid leukaemia

A myeloproliferative disorder caused by a constitutively active BCR-ABL tyrosinase kinase. It has been found that continuous treatment of chronic phase chronic myeloid leukaemia with the drug imatinib can induce durable responses of five years or more in a high proportion of patients
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Roz spent years basing her self-worth on how much she weighed, but it took her sister Rachel to be diagnosed with chronic myeloid leukaemia for her outlook to change.
(8.) Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Mailekavu SB, Lakkavalli RK, Haleshappa RA, Prognostic and predictive implication of Sokal, Euro and Eutos scores in chronic myeloid leukaemia in imatinib era-experience from a tertiary oncology centre in Southern India, Ecancer 10: 679 (2016).
Prognostic and predictive implications of Sokal, Euro and EutoS scores in chronic myeloid leukaemia in the imatinib era experience from a tertiary oncology centre in Southern India.
Researchers at the University of Glasgow's Institute of Cancer Sciences were granted PS3.1million by Cancer Research UK for their work into chronic myeloid leukaemia (CML).
During the hospital stay blood morphology, bone marrow aspiration and BCR-ABL were done to confirm the diagnosis of chronic myeloid leukaemia. Our report thus explains the relevance of all physicians in the diagnosis and management of patients with priapism.
Dr Cortes is deputy chair and professor of medicine in the Department of Leukemia at MD Anderson Cancer Centre, where he directs the Chronic Myeloid Leukaemia (CML) and Acute Myeloid Leukaemia (AML) Programs.
Apperley, "Managing pregnancy in chronic myeloid leukaemia," Annals of Hematology, vol.
Goldman, "Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period," British Journal of Haematology, vol.
Apperley, "Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia," The Lancet Oncology, vol.
Copland, "How I manage priapism in chronic myeloid leukaemia patients," British Journal of Haematology, vol.
Guilhot et al., "Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial," The Lancet Oncology, vol.

Full browser ?